Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2

Journal of Immunotherapy
Peter AttiaSteven A Rosenberg

Abstract

CD4(+)CD25(+) T-regulatory cells (T(reg)) can inhibit the proliferation and cytokine secretion of CD4(+)CD25(-) helper T cells in mice and humans. In murine tumor models, the presence of these T(reg) cells can inhibit the antitumor effectiveness of T-cell transfer and active immunization approaches. We have thus initiated efforts to eliminate T(reg) cells selectively from human peripheral blood mononuclear cells (PBMCs) to potentially bolster antitumor responses. LMB-2 is a recombinant immunotoxin that is a fusion of a single-chain Fv fragment of the anti-Tac anti-CD25 monoclonal antibody to a truncated form of the bacterial Pseudomonas exotoxin A. In vitro incubation of human PBMCs with LMB-2 reduced the levels of CD4(+)CD25(+) and Foxp3-expressing cells without impairing the function of the remaining lymphocytes. The short in vivo half-life of LMB-2 makes it an attractive candidate for reducing human T(reg) cells in vivo before the administration of cancer vaccine or cell transfer immunotherapy approaches.

References

Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·G WalzT B Strom
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J KreitmanI Pastan
Jan 7, 2003·Journal of Immunotherapy·Luv Ram Javia, Steven A Rosenberg
Jun 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Giao Q PhanSteven A Rosenberg
Aug 20, 2003·The Journal of Experimental Medicine·Willem W OverwijkNicholas P Restifo
Sep 10, 2003·Journal of Leukocyte Biology·Thomas R Malek
Jul 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Manuelle ViguierLaurent Ferradini
Jul 23, 2004·Expert Opinion on Biological Therapy·Robert J Kreitman
Feb 24, 2005·Journal of Immunotherapy·Paul Andrew Antony, Nicholas P Restifo
Feb 25, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Paul A AntonyNicholas P Restifo
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark E DudleySteven A Rosenberg
Jul 8, 2005·Journal of Immunotherapy·Daniel J PowellSteven A Rosenberg
Aug 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J KreitmanIra Pastan

❮ Previous
Next ❯

Citations

Jul 5, 2006·Cancer Immunology, Immunotherapy : CII·Keith L KnutsonLupe G Salazar
May 16, 2007·Cancer Immunology, Immunotherapy : CII·Sandra TuyaertsAude Bonehill
Sep 28, 2007·Cancer Immunology, Immunotherapy : CII·Fiona C ThistlethwaiteRobert E Hawkins
Apr 2, 2008·Current Oncology Reports·Marc Beyer, Joachim L Schultze
Apr 20, 2006·Nature Reviews. Immunology·Luca GattinoniNicholas P Restifo
Jun 30, 2007·Hybridoma·Robyn S AriasAlan L Epstein
Feb 3, 2007·Current Opinion in Oncology·Giorgio ParmianiLicia Rivoltini
Apr 9, 2009·Pathology International·Noriyuki SatoToshihiko Torigoe
Oct 25, 2006·Annual Review of Medicine·Ira PastanRobert J Kreitman
Nov 24, 2011·Clinical & Developmental Immunology·Nona JanikashviliNicolas Larmonier
Jul 11, 2012·Clinical & Developmental Immunology·R CornelissenJ P J J Hegmans
May 3, 2012·Cancer Research·Andrea FacciabeneGeorge Coukos
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chrystal M PaulosNicholas P Restifo
Nov 10, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rajat SinghRobert J Kreitman
Feb 18, 2010·Immunotherapy·Nona JanikashviliEmmanuel Katsanis
Nov 15, 2012·Immunotherapy·Robin CornelissenJoachim G Aerts
Mar 26, 2014·Expert Opinion on Biological Therapy·Belal ChaudharyEyad Elkord
Oct 16, 2014·Journal for Immunotherapy of Cancer·Seth M PollackCassian Yee
Mar 2, 2010·Biochimica Et Biophysica Acta·S NizarA Dalgleish
May 1, 2007·Biomolecular Engineering·David Filpula
Mar 28, 2008·Immunological Reviews·Duane A MitchellJohn H Sampson
May 29, 2014·International Journal of Hepatology·Kahori SetoKoji Kawakami
May 16, 2008·Expert Opinion on Therapeutic Targets·Christian KoeneckeAnke Franzke
Dec 22, 2007·Expert Opinion on Drug Delivery·Michael J BrumlikTyler J Curiel
Jun 24, 2015·Journal of Immunology Research·Michelle H NelsonChrystal M Paulos
May 13, 2017·Nature Reviews. Neurology·Michael WellerJohn H Sampson
Oct 13, 2018·Nature Reviews. Drug Discovery·Amir SharabiGeorge C Tsokos
Aug 2, 2007·Journal of Immunotherapy·Hans J J van der VlietMark A Exley
Oct 25, 2007·Nature Reviews. Cancer·Mario P Colombo, Silvia Piconese
Feb 15, 2019·Proceedings of the National Academy of Sciences of the United States of America·Masanori OndaIra Pastan
Apr 23, 2009·British Journal of Cancer·S NizarA Dalgleish
Jul 31, 2019·Immunotherapy·Pankaj KumarWilliam Bishai
Aug 10, 2017·Expert Opinion on Emerging Drugs·Anna Wolska-WasherTadeusz Robak
Nov 10, 2013·Cancers·Brian J AhnHideho Okada
Sep 20, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Daniel J PowellIra Pastan
Oct 14, 2014·Molecular Medicine Reports·Bohan DongJun Lv
Apr 18, 2012·Journal of Immunotoxicology·Akbar Akbari, Abbas Rezaei
Nov 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicolas LarmonierEmmanuel Katsanis
Jul 20, 2007·Cancer Research·Jennifer B JacobWei-Zen Wei
Sep 10, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert J KreitmanIra Pastan
Jun 25, 2021·International Immunopharmacology·Alexander Batista-DuharteRafael Solana

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.